Drug Trial Radar · NCT07002034
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Reunion Neuroscience IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Conditions
- Adjustment Disorder
Interventions
RE104 for InjectionDrug
Single, subcutaneous dose of RE104 for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total scoreTime frame: Day 7
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
UAB, Psychiatry and Behavioral Neurology
Birmingham, Alabama · Recruiting
University of Arizona
Tucson, Arizona · Recruiting
Kadima Neuropsychiatry Institute
San Diego, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Terminated
University of Colorado
Aurora, Colorado · Recruiting
University of South Florida, Department of Psychiatry and Behavioral Neuroscience
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Hawaii Pacific Neuroscience
Honolulu, Hawaii · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
The University of Kansas Medical Center
Kansas City, Kansas · Recruiting
LSU Health Shreveport
Shreveport, Louisiana · Recruiting
Sunstone Therapies, PC
Rockville, Maryland · Recruiting
Sheppard Pratt
Towson, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Massachusetts Chan Medical Center
Worcester, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Health
Novi, Michigan · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
University of New Mexico, School of Medicine
Albuquerque, New Mexico · Recruiting
Roswell Park Center Institute
Buffalo, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
New York State Psychiatric Institute
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University, Department of Psychiatry
Columbus, Ohio · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Alliance for Multispecialty Research Clinical
Knoxville, Tennessee · Recruiting
Dell Medical School, University of Texas at Austin
Austin, Texas · Recruiting
Cedar Clinical Research Inc.
Draper, Utah · Recruiting
UVA Center for Psychiatric Clinical Research
Charlottesville, Virginia · Recruiting
Seattle Neuropsychiatric Treatment Center
Seattle, Washington · Recruiting
University of Wisconsin at Madison
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.